JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB258756

Human VAC14 knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

VAC14 KO cell lysate available now. KO validated. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1 and 1 bp insertion in exon1.
2 Images
Sanger Sequencing - Human VAC14 knockout HeLa cell lysate (AB258756)
  • Sanger seq

Unknown

Sanger Sequencing - Human VAC14 knockout HeLa cell lysate (AB258756)

Allele-2 : 1 bp insertion in exon1

Sanger Sequencing - Human VAC14 knockout HeLa cell lysate (AB258756)
  • Sanger seq

Unknown

Sanger Sequencing - Human VAC14 knockout HeLa cell lysate (AB258756)

Allele-1 : 1 bp deletion in exon1

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1 and 1 bp insertion in exon1.

Disease

Adenocarcinoma

style
left-column

Complementary Products

Cell Lines & Lysates

AB265295

Human VAC14 knockout HeLa cell line

Sanger Sequencing - Human VAC14 knockout HeLa cell line (AB265295)

  • 0
  • 0
style
left-column

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

style
left-column

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab258756-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human VAC14 knockout HeLa cell lysate", "number":"AB258756-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB258756-CMP02", "productcode":"" } ] } } }
style
left-column

Properties and storage information

Gene name
VAC14
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

VAC14 also known as ArPIKfyve is a regulatory protein with a molecular weight of roughly 100 kDa. It is expressed in various tissues but particularly notable in the brain. Mechanically VAC14 works with FIG4 and PIKFYVE in a complex that regulates the levels of phosphatidylinositol 35-bisphosphate (PI(35)P2) in cells. It interacts directly with PIKFYVE to control its kinase activity which is important for maintaining the balance of phosphoinositides.
Biological function summary

VAC14 takes an important role in phosphoinositide metabolism and is part of the PIKfyve complex which consists of PIKFYVE and FIG4. This complex regulates the synthesis of PI(35)P2 a lipid second messenger involved in various cellular processes. Through this regulation VAC14 influences membrane trafficking endosome-to-lysosome transport and lysosomal homeostasis. Proper functioning of VAC14 is essential for cellular integrity and response to environmental changes especially in neuronal cells.

Pathways

VAC14 involves itself in the phosphoinositide signaling pathway and the lysosomal pathway. This protein forms a module with PIKFYVE and FIG4 to control the production of PI(35)P2 which is important for endolysosomal dynamics. VAC14’s activity influences autophagic flux and endosomal maturation processes integral to cellular homeostasis. The modulation of these pathways ensures proper intracellular processing and material degradation which is linked to cellular health and stress responses.

VAC14 has associations with Charcot-Marie-Tooth disease (CMT) and fibrotic lung disease. Mutations affecting VAC14 can lead to the malformation of neuronal axons and defects in both motor and sensory neurons in CMT. In these diseases VAC14 interacts with FIG4 where mutations in either protein can disrupt PI(35)P2 levels leading to neuropathy. Understanding the role of VAC14 in these contexts opens avenues for targeted therapeutic interventions in related neurological and fibrotic disorders.
style
left-column

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

style
left-column

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

style
left-column

Product protocols

style
left-column
style
left-column
style
right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com